Free Trial
NASDAQ:GH

Guardant Health (GH) Stock Price, News & Analysis

Notice: Trading of Guardant Health halted at 06:55 AM EST due to "News pending".
$23.13
+0.62 (+2.75%)
(As of 08:09 AM ET)
Today's Range
$23.13
$23.13
50-Day Range
$16.07
$26.24
52-Week Range
$15.81
$41.06
Volume
729 shs
Average Volume
1.96 million shs
Market Capitalization
$2.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.78

Guardant Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
54.7% Upside
$35.78 Price Target
Short Interest
Bearish
8.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.51
Upright™ Environmental Score
News Sentiment
-0.15mentions of Guardant Health in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$38,972 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.49) to ($3.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

99th out of 920 stocks

Medical Laboratories Industry

5th out of 19 stocks

GH stock logo

About Guardant Health Stock (NASDAQ:GH)

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

GH Stock Price History

GH Stock News Headlines

Guardant Health Inc.
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
5/23/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Employees
1,779
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.78
High Stock Price Target
$50.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+58.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-479,450,000.00
Pretax Margin
-76.20%

Debt

Sales & Book Value

Annual Sales
$563.95 million
Book Value
$0.56 per share

Miscellaneous

Free Float
114,782,000
Market Cap
$2.75 billion
Optionable
Not Optionable
Beta
0.92
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Helmy Eltoukhy Ph.D. (Age 44)
    Co-Founder, Co-CEO & Chairman
    Comp: $11.63k
  • Dr. AmirAli Talasaz Ph.D. (Age 44)
    Co-CEO & Director
    Comp: $11.18k
  • Mr. Michael Bell (Age 55)
    Chief Financial Officer
    Comp: $630.99k
  • Mr. John G. Saia (Age 51)
    Chief Legal Officer & Corporate Secretary
    Comp: $627.18k
  • Dr. Craig Eagle M.D. (Age 57)
    Chief Medical Officer
    Comp: $649.13k
  • Mr. Christopher Freeman (Age 50)
    Chief Commercial Officer
    Comp: $630.39k
  • Ms. Darya Chudova
    Chief Technology Officer
  • Mr. Kumud KaliaMr. Kumud Kalia (Age 58)
    Chief Information Officer
  • Ms. Jennifer Higgins
    Vice President of Public Affairs
  • Ms. Terilyn Juarez Monroe (Age 57)
    Chief People Officer

GH Stock Analysis - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GH shares.
View GH analyst ratings
or view top-rated stocks.

What is Guardant Health's stock price target for 2024?

12 analysts have issued 1-year price objectives for Guardant Health's shares. Their GH share price targets range from $27.00 to $50.00. On average, they predict the company's share price to reach $35.78 in the next year. This suggests a possible upside of 54.7% from the stock's current price.
View analysts price targets for GH
or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2024?

Guardant Health's stock was trading at $27.05 at the beginning of the year. Since then, GH stock has decreased by 14.5% and is now trading at $23.13.
View the best growth stocks for 2024 here
.

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our GH earnings forecast
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($1.25) by $0.58. The business earned $137.15 million during the quarter, compared to analysts' expectations of $129.44 million. Guardant Health had a negative trailing twelve-month return on equity of 246.47% and a negative net margin of 76.34%. The company's revenue was up 25.7% on a year-over-year basis. During the same period last year, the firm earned ($2.25) EPS.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $675.0 million-$685.0 million, compared to the consensus revenue estimate of $664.0 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

Guardant Health (GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.40%), Baillie Gifford & Co. (5.12%), Capital International Investors (3.12%), Price T Rowe Associates Inc. MD (1.26%), Jennison Associates LLC (0.40%) and Mitsubishi UFJ Trust & Banking Corp (0.33%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Meghan V Joyce, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends
.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GH) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners